Raheja H, et al. - Researchers analyzed data from randomized control trials (RCT) and observational studies comparing dual antiplatelet therapy (DAPT) with single anti-platelet therapy (SAPT) following transcatheter aortic valve replacement (TAVR). They identified these studies from PubMed, EMBASE, the Cochrane Central Register of Controlled trials, and the clinical trial registry. They used a random-effects model assuming inter-study heterogeneity to compare event rates using a forest plot of relative risk with 95% confidence intervals. Ultimately, the analysis of six studies (3 RCTs and 3 observational studies, n = 840) revealed no difference between SAPT and DAPT in preventing stroke, myocardial infarction or death while the risk of bleeding was higher with DAPT.